Sight Diagnostics completes US$28.7 million Series C funding

Consumer digital health fund Longliv Ventures has led the $27.8 million  Series C funding for Sight Diagnostics, a Tel Aviv-based company that provides patients with lab-grade complete blood count test results by finger prick in minutes.

Other participants in the round include Jack Nicklaus II, a healthcare philanthropist and board member of the Nicklaus Children’s Health Care Foundation, Steven Esrick, a healthcare impact investor, and an additional major medical equipment manufacturer, as well as existing investors OurCrowd, Go Capital, and New Alliance Capital.

“Sight’s mission is to improve health by providing fast, accurate, and pain-free testing when and where it is needed,” said Yossi Pollak, chief executive of Sight Diagnostics. “The company will use the funding first and foremost to ramp up the global expansion of OLO, Sight’s lab-grade point-of-care blood diagnostics system, and with Longliv Ventures as a strategic investor we look forward to an effective and rapid expansion of our sales.”

Following this investment, Dan Eldar, executive director of Longliv Ventures, will join the board of directors of Sight.

“We believe Sight Diagnostics is set to revolutionize medical processes in many types of clinical settings, as well as to give rise to new services at retail points of care,” said David Gordon, head of investments of Longliv Ventures.

Founded in 2010, Sight Diagnostics says that it aims to bring affordable, scalable and accurate blood diagnostics to the point-of-care, accelerating better patient outcomes and improving healthcare. It has developed an artificial intelligence-driven platform for blood analysis and infectious disease diagnostics based on its proprietary machine-vision technology. Sight’s technology was first deployed in 2014 to detect malaria using digital fluorescent microscopy.